Rothschild & Co. Asset Management US Inc. increased its position in Syneos Health Inc (NASDAQ:SYNH) by 35.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 789,036 shares of the company’s stock after purchasing an additional 205,947 shares during the period. Rothschild & Co. Asset Management US Inc. owned approximately 0.76% of Syneos Health worth $40,312,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. AlphaOne Investment Services LLC raised its position in Syneos Health by 29.0% in the 1st quarter. AlphaOne Investment Services LLC now owns 1,590 shares of the company’s stock worth $82,000 after buying an additional 357 shares during the last quarter. Private Capital Group LLC raised its position in Syneos Health by 75.5% in the 1st quarter. Private Capital Group LLC now owns 3,201 shares of the company’s stock worth $166,000 after buying an additional 1,377 shares during the last quarter. Starr International Co. Inc. purchased a new position in Syneos Health in the 1st quarter worth about $167,000. Adams Diversified Equity Fund Inc. purchased a new position in Syneos Health in the 1st quarter worth about $295,000. Finally, Convergence Investment Partners LLC purchased a new position in Syneos Health in the 1st quarter worth about $308,000.
SYNH has been the subject of a number of recent analyst reports. Barclays reissued a “hold” rating and issued a $48.00 target price on shares of Syneos Health in a research report on Wednesday, April 17th. ValuEngine lowered Syneos Health from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Finally, Zacks Investment Research raised shares of Syneos Health from a “sell” rating to a “hold” rating in a research report on Friday, May 24th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Syneos Health has an average rating of “Buy” and an average target price of $53.33.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.08. Syneos Health had a net margin of 0.42% and a return on equity of 9.55%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the firm earned $0.55 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, analysts predict that Syneos Health Inc will post 2.67 EPS for the current year.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: How Does the Quiet Period Work?
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.